• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

    4.500 +0.140 (+3.21%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Myriad Genetics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    News headline image
    Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
    What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
    Via StockStory
    Topics Government Stocks
    News headline image
    Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
    Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Inc (NASDAQ:MYGN) Stock Surges 19.6% on Strong Q4 Earnings Beat ↗
    Via Chartmill
    News headline image
    2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off
    "You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
    Via StockStory
    News headline image
    Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc
    Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    3 Reasons to Sell MYGN and 1 Stock to Buy Instead
    Shareholders of Myriad Genetics would probably like to forget the past six months even happened. The stock dropped 31.8% and now trades at $5.24. This may ha... 
    Via StockStory
    News headline image
    Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know
    What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha... 
    Via StockStory
    Topics Artificial Intelligence Earnings
    News headline image
    3 Stocks Under $10 We Keep Off Our Radar
    Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many ... 
    Via StockStory
    News headline image
    2 Unprofitable Stocks on Our Buy List and 1 We Brush Off
    Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
    Via StockStory
    News headline image
    Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
    What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5.9% in the afternoon session after the company announced the launch of... 
    Via StockStory
    Topics Earnings Economy Stocks
    News headline image
    Myriad Commercially Launches Precise MRD with Select Community Oncologists
    Launch Represents Significant Step to Broader Commercialization 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know
    A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key... 
    Via StockStory
    Topics Economy Government Stocks
    News headline image
    Why Myriad Genetics (MYGN) Stock Is Trading Up Today
    Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 4.9% in the morning session after the company reported better-than-expected fourth-quarter 2025 earnings that surpassed analyst... 
    Via StockStory
    Topics Government World Trade
    News headline image
    Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    Myriad Genetics (MYGN) Q4 2025 Earnings Transcript ↗
    Myriad Genetics (MYGN) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Myriad Genetics’s (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22%
    Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full... 
    Via StockStory
    News headline image
    Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    iRhythm, agilon health, GoodRx, Fortrea, and Myriad Genetics Stocks Trade Down, What You Need To Know
    A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court... 
    Via StockStory
    Topics Government World Trade
    News headline image
    FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
    Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
    Management will participate in three upcoming investor healthcare conferences 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    3 Cash-Burning Stocks We Keep Off Our Radar
    Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
    Via StockStory
    Topics Bankruptcy
    News headline image
    1 Small-Cap Stock on Our Watchlist and 2 That Underwhelm
    Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
    Via StockStory
    News headline image
    Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
    Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
    Via StockStory
    Topics Economy Stocks
    News headline image
    Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    3 Stocks Under $10 We Think Twice About
    Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
    Via StockStory
    News headline image
    3 Unprofitable Stocks That Fall Short
    Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
    Via StockStory
    News headline image
    Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
    Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 3.7% in the afternoon session after the company signed an exclusive agreement with Zydus Lifesciences to commercialize a trio of... 
    Via StockStory
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.